GlobeNewsWire · AMRN · October 25, 2026
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗